Home > Urology > EAU 2020 > Docetaxel + hormonal therapy: improved prostate cancer PFS

Docetaxel + hormonal therapy: improved prostate cancer PFS

Adding docetaxel to antiandrogen treatment improves progression-free survival (PFS) in prostate cancer patients with prostate-specific antigen (PSA) relapse.

Dr Andreas Josefsson (Sahlgrenska University Hospital, Göteborg, Sweden) presented the SPCG-14 study, a prospective, multicentre, phase 2 clinical trial of bicalutamide alone or with the addition of docetaxel in nonmetastatic prostate cancer with a rising PSA [1]. This trial assessed whether any benefit is gained by adding docetaxel-based chemotherapy to hormonal therapy alone in the population of prostate cancer patients who have only biochemically relapsed disease after curative treatment (PSA doubling time is <12 months). The investigators hypothesised further that the approach is likely to be more effective at a time of minimal tumour burden, prior to radiographic relapse, resulting in minimisation of the overall burden of therapy and b...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on